ASCO Annual Meeting

4-Drug Regimen Boosts Time to Progression in Newly Diagnosed Myeloma

June 8th 2024, 2:00pm

Article

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Patients With Stage 3 Melanoma Should Discuss Adjuvant Therapy

June 7th 2024, 9:00pm

Video

Patients with resectable stage 3 melanoma should talk about pretreatment therapy with their cancer care teams, an expert said.

Padcev Plus Keytruda Doesn’t Worsen Quality of Life in Bladder Cancer

June 7th 2024, 7:00pm

Article

Padcev and Keytruda improve survival and progression among patients with bladder cancer, but don’t adversely impact pain, functioning or quality of life.

Trodelvy Improves Quality of Life Over Chemo in TNBC

June 6th 2024, 9:00pm

Video

Trodelvy led to better disease control and improved quality of life compared to chemotherapy in patients with triple-negative breast cancer.

Keytruda Plus Chemo May Improve Penile Cancer Outcomes

June 6th 2024, 7:00pm

Article

Keytruda plus platinum-based chemotherapy appeared to be safe and effective in treating penile squamous cell carcinoma.

Padcev Improves Outcomes for Cisplatin-Ineligible Bladder Cancer

June 6th 2024, 3:00pm

Article

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

Opdivo Before and After Surgery Improves Event-Free Survival in NSCLC

June 4th 2024, 9:00pm

Article

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

Dato-DXd Improves Antitumor Intracranial Responses in NSCLC Subgroups

June 4th 2024, 3:06pm

Article

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Vaccine-Based Combo Shows Disease Control in CRC

June 4th 2024, 1:00pm

Article

PolyPEPI1018 may boost the efficacy of Tecentriq in certain patients with colorectal cancer.

Belamaf Regimen Improves Progression-Free Survival in Myeloma

June 3rd 2024, 9:00pm

Article

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.